Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Interest Expenses (2020 - 2025)

Historic Interest Expenses for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $7.3 million.

  • Xeris Biopharma Holdings' Interest Expenses fell 641.03% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.7 million, marking a year-over-year decrease of 45.57%. This contributed to the annual value of $30.5 million for FY2024, which is 1462.29% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Interest Expenses is $7.3 million, which was down 641.03% from $7.4 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Interest Expenses ranged from a high of $8.0 million in Q2 2024 and a low of $1.8 million during Q1 2021
  • Over the past 5 years, Xeris Biopharma Holdings' median Interest Expenses value was $6.5 million (recorded in 2023), while the average stood at $5.4 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Interest Expenses tumbled by 6086.96% in 2021, and later skyrocketed by 14261.11% in 2022.
  • Xeris Biopharma Holdings' Interest Expenses (Quarter) stood at $1.8 million in 2021, then soared by 142.61% to $4.4 million in 2022, then soared by 60.5% to $7.0 million in 2023, then rose by 9.86% to $7.7 million in 2024, then decreased by 5.19% to $7.3 million in 2025.
  • Its last three reported values are $7.3 million in Q3 2025, $7.4 million for Q2 2025, and $7.3 million during Q1 2025.